Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kellie S Reynolds

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology and Therapeutics|July 17, 2015
Developing and Using Therapeutics for Emerging InfectionsJeannine S McCune, Kellie S Reynolds
Journal of Clinical Pharmacology|July 2, 2022
Using Endogenous Biomarkers to Derisk Assessment of Transporter-Mediated Drug-Drug Interactions: A Scientific PerspectiveVikram Arya, Kellie S Reynolds, Xinning Yang
Toxicology and Applied Pharmacology|January 5, 2010
Drug interactions evaluation: an integrated part of risk assessment of therapeuticsLei Zhang, Kellie S Reynolds, Ping Zhao, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2021
Variations in pharmacokinetic-pharmacodynamic target values across MICs and their potential impact on determination of susceptibility test interpretive criteriaUrsula Waack, Abhay Joshi, Seong H Jang, et al.
Antimicrobial Agents and Chemotherapy|March 8, 2022
Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Renal ImpairmentLuning Zhuang, Kunyi Wu, Seong H Jang, et al.
Journal of Clinical Pharmacology|March 10, 2020
Evaluation of Hemodialysis Effect on Pharmacokinetics of Meropenem/Vaborbactam in End-Stage Renal Disease Patients Using Modeling and SimulationLuning Zhuang, Yichao Yu, Xiaohui Wei, et al.
Journal of Clinical Pharmacology|February 28, 2008
Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampinJennifer L DiGiacinto, Kirk M Chan-Tack, Sarah M Robertson, et al.
Journal of Clinical Pharmacology|November 12, 2013
Does an increase in serum creatinine always reflect renal injury? The case of Stribild®Vikram Arya, Jeffry Florian, Kendall A Marcus, et al.
Clinical Pharmacology and Therapeutics|July 6, 2022
Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement TherapyXiaohui Wei, Shabnam Naseer, Edward A Weinstein, et al.
Clinical Pharmacokinetics|September 28, 2014
Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug AdministrationChristian Wagner, Yuzhuo Pan, Vicky Hsu, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|July 17, 2015
Developing and Using Therapeutics for Emerging InfectionsJeannine S McCune, Kellie S Reynolds
Journal of Clinical Pharmacology|July 2, 2022
Using Endogenous Biomarkers to Derisk Assessment of Transporter-Mediated Drug-Drug Interactions: A Scientific PerspectiveVikram Arya, Kellie S Reynolds, Xinning Yang
Toxicology and Applied Pharmacology|January 5, 2010
Drug interactions evaluation: an integrated part of risk assessment of therapeuticsLei Zhang, Kellie S Reynolds, Ping Zhao, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2021
Variations in pharmacokinetic-pharmacodynamic target values across MICs and their potential impact on determination of susceptibility test interpretive criteriaUrsula Waack, Abhay Joshi, Seong H Jang, et al.
Antimicrobial Agents and Chemotherapy|March 8, 2022
Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Renal ImpairmentLuning Zhuang, Kunyi Wu, Seong H Jang, et al.
Journal of Clinical Pharmacology|March 10, 2020
Evaluation of Hemodialysis Effect on Pharmacokinetics of Meropenem/Vaborbactam in End-Stage Renal Disease Patients Using Modeling and SimulationLuning Zhuang, Yichao Yu, Xiaohui Wei, et al.
Journal of Clinical Pharmacology|February 28, 2008
Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampinJennifer L DiGiacinto, Kirk M Chan-Tack, Sarah M Robertson, et al.
Journal of Clinical Pharmacology|November 12, 2013
Does an increase in serum creatinine always reflect renal injury? The case of Stribild®Vikram Arya, Jeffry Florian, Kendall A Marcus, et al.
Clinical Pharmacology and Therapeutics|July 6, 2022
Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement TherapyXiaohui Wei, Shabnam Naseer, Edward A Weinstein, et al.
Clinical Pharmacokinetics|September 28, 2014
Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug AdministrationChristian Wagner, Yuzhuo Pan, Vicky Hsu, et al.
Pageof 3